Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases.

Spero intends to use the REPAIR investment to advance its SPR720 program. SPR720 is Spero’s oral antibiotic being developed for the treatment of non-tuberculous mycobacterial (NTM) infections.